<SEC-DOCUMENT>0001415889-24-010417.txt : 20240405
<SEC-HEADER>0001415889-24-010417.hdr.sgml : 20240405
<ACCEPTANCE-DATETIME>20240405163043
ACCESSION NUMBER:		0001415889-24-010417
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240403
FILED AS OF DATE:		20240405
DATE AS OF CHANGE:		20240405

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Skynner Michael
		CENTRAL INDEX KEY:			0001776582
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38916
		FILM NUMBER:		24826935

	MAIL ADDRESS:	
		STREET 1:		C/O BICYCLE THERAPEUTICS LIMITED
		STREET 2:		B900 BABRAHAM RESEARCH CAMPUS
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB223AT

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BICYCLE THERAPEUTICS plc
		CENTRAL INDEX KEY:			0001761612
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000

	BUSINESS ADDRESS:	
		STREET 1:		BLOCKS A & B, PORTWAY BUILDING
		STREET 2:		GRANTA PARK, GREAT ABINGTON
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB21 6GS
		BUSINESS PHONE:		011441223261503

	MAIL ADDRESS:	
		STREET 1:		BLOCKS A & B, PORTWAY BUILDING
		STREET 2:		GRANTA PARK, GREAT ABINGTON
		CITY:			CAMBRIDGE
		STATE:			X0
		ZIP:			CB21 6GS

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BICYCLE THERAPEUTICS Ltd
		DATE OF NAME CHANGE:	20181212
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>form4-04052024_040436.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2024-04-03</periodOfReport>

    <issuer>
        <issuerCik>0001761612</issuerCik>
        <issuerName>BICYCLE THERAPEUTICS plc</issuerName>
        <issuerTradingSymbol>BCYC</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001776582</rptOwnerCik>
            <rptOwnerName>Skynner Michael</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O BICYCLE THERAPEUTICS PLC</rptOwnerStreet1>
            <rptOwnerStreet2>BLOCKS A &amp; B, PORTWAY BUILDING</rptOwnerStreet2>
            <rptOwnerCity>CAMBRIDGE</rptOwnerCity>
            <rptOwnerState>X0</rptOwnerState>
            <rptOwnerZipCode>CB21 6GS</rptOwnerZipCode>
            <rptOwnerStateDescription>UNITED KINGDOM</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>false</isDirector>
            <isOfficer>true</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
            <officerTitle>CHIEF TECHNOLOGY OFFICER</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>0</aff10b5One>

    <nonDerivativeTable>
        <nonDerivativeTransaction>
            <securityTitle>
                <value>Ordinary Shares</value>
            </securityTitle>
            <transactionDate>
                <value>2024-04-03</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>S</transactionCode>
                <equitySwapInvolved>0</equitySwapInvolved>
                <footnoteId id="F1"/>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>955</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>23.81</value>
                    <footnoteId id="F2"/>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>D</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>94884</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value></value>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeTransaction>
    </nonDerivativeTable>

    <derivativeTable></derivativeTable>

    <footnotes>
        <footnote id="F1">Represents the number of shares required to be sold to cover the statutory tax withholding obligations in connection with the vesting and settlement of the RSUs. This sale is mandated by the Reporting Person's award agreement that requires the satisfaction of tax withholding obligations to be funded by a &quot;sell to cover&quot; transaction and does not represent a discretionary sale by the Reporting Person.</footnote>
        <footnote id="F2">The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.75 to $24.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jason Minio, Attorney-in-Fact</signatureName>
        <signatureDate>2024-04-05</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
